Cantor Fitzgerald targets Lexicon Pharmaceuticals stock at USD 8.00

Published on 10/02/2026 at 01:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor Fitzgerald set USD 8.00 target on September 28, 2026. Lexicon Pharmaceuticals stock was EUR 1.66 on September 29, 2026 versus EUR 1.67.

LXRX, US5288723027, Illustration mit AI erstellt.

Lexicon Pharmaceuticals (US5288723027) drew a new USD 8.00 price target from Cantor Fitzgerald on September 28, 2026, when the firm initiated coverage with an Overweight rating, according to Investing.com. The call centers on sotagliflozin and Lexicon's late-stage heart-disease program.

SONATA-HCM clears enrollment hurdle

Lexicon completed enrollment in its Phase 3 SONATA-HCM study of sotagliflozin for hypertrophic cardiomyopathy, with more than the planned 500 patients enrolled. MarketBeat reported the milestone on September 20, 2026, and said topline results are expected in the first quarter of 2027.

The study covers obstructive and non-obstructive forms of the disease. Its design gives sotagliflozin a route to complement cardiac myosin inhibitors, a point highlighted in the Cantor coverage described by Yahoo Finance on September 28, 2026.

Quarterly loss keeps risk visible

Lexicon reported second-quarter 2026 revenue of USD 0.69 million and a diluted loss of USD 0.07 per share, versus a consensus loss of USD 0.05 per share, according to MarketBeat. Revenue was also below the USD 3.99 million analyst estimate cited in the same report, leaving clinical execution and financing capacity central to the investment case.

The contrast is clear: the company has a fully enrolled pivotal study, but its second-quarter loss exceeded the consensus loss by USD 0.02 per share. Cantor's USD 8.00 target therefore rests on future clinical progress rather than current earnings power.

Tradegate quote remains below yearly high

Lexicon Pharmaceuticals stock was last at EUR 1.66 on Tradegate on September 29, 2026 at 3:57 p.m. CEST, down 0.24 percent versus the EUR 1.67 prior close. The same quote page showed a EUR 0.93 to EUR 2.34 52-week range, placing the stock 29.00 percent below its high.

Market capitalization stood at USD 808.4 million as of October 1, 2026, while the Nasdaq listing was quoted at USD 1.82 after hours on that date. The next major valuation test is the first-quarter 2027 SONATA-HCM data readout, with the study's enrollment milestone already complete. Price source: substitute price Tradegate, Lang & Schwarz without data set.